![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: preliminary analysis of 2 Phase 1b studies including an analytical treatment interruption
|
|
|
oral at EACS 2023 Oct 20
![1024231](../images/102423/102423-3/1024231.gif)
![1024232](../images/102423/102423-3/1024232.gif)
![1024233](../images/102423/102423-3/1024233.gif)
![1024234](../images/102423/102423-3/1024234.gif)
![1024235](../images/102423/102423-3/1024235.gif)
![1024236](../images/102423/102423-3/1024236.gif)
![1024237](../images/102423/102423-3/1024237.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|